Reports of altered epigenetic histone modifications in cancer cells have focused on individual gene promoters and so far none of these changes has been related to clinical outcome. Now aberrations of ‘global’ histone modification have been observed in prostate tumour patients. These do relate to clinical outcome, and suggest a useful means of prognosis.